Mp15-05 Prognostic Value of Tumor-Agnostic Circulating Tumor Dna Testing in Muscle-Invasive Bladder Cancer

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP15)1 May 2024MP15-05 PROGNOSTIC VALUE OF TUMOR-AGNOSTIC CIRCULATING TUMOR DNA TESTING IN MUSCLE-INVASIVE BLADDER CANCER Raquel Carrasco, Mercedes Ingelmo-Torres, Ramón Trullas, Fiorella L. Roldán, Leonardo Rodríguez-Carunchio, Marcel Figueras, Claudia Mercader, Bernat Padullés, Jasmine L. Olegario, Joan Sureda, Antonio Alcaraz, Laura Izquierdo, and Lourdes Mengual Raquel CarrascoRaquel Carrasco , Mercedes Ingelmo-TorresMercedes Ingelmo-Torres , Ramón TrullasRamón Trullas , Fiorella L. RoldánFiorella L. Roldán , Leonardo Rodríguez-CarunchioLeonardo Rodríguez-Carunchio , Marcel FiguerasMarcel Figueras , Claudia MercaderClaudia Mercader , Bernat PadullésBernat Padullés , Jasmine L. OlegarioJasmine L. Olegario , Joan SuredaJoan Sureda , Antonio AlcarazAntonio Alcaraz , Laura IzquierdoLaura Izquierdo , and Lourdes MengualLourdes Mengual View All Author Informationhttps://doi.org/10.1097/01.JU.0001009500.87761.bf.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). METHODS: Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in patients' plasma samples by droplet digital PCR to determine their ctDNA status. RESULTS: During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and four and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p<0.05; Figure 1). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p=0.045; Figure 2). CONCLUSIONS: Longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in the clinical setting could improve disease management and patients' outcomes. Download PPTDownload PPT Source of Funding: Instituto de Salud Carlos III (ISCIII): project references number PI20/00409 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e230 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Raquel Carrasco More articles by this author Mercedes Ingelmo-Torres More articles by this author Ramón Trullas More articles by this author Fiorella L. Roldán More articles by this author Leonardo Rodríguez-Carunchio More articles by this author Marcel Figueras More articles by this author Claudia Mercader More articles by this author Bernat Padullés More articles by this author Jasmine L. Olegario More articles by this author Joan Sureda More articles by this author Antonio Alcaraz More articles by this author Laura Izquierdo More articles by this author Lourdes Mengual More articles by this author Expand All Advertisement PDF downloadLoading ...